ArticleCell reports2019
Characterization of Tumor-Suppressor Gene Inactivation Events in 33 Cancer Types.
Article in Cell reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 32 citations in OpenAlex.
- Genetic Medicine Approaches for Tumor Suppressor Loss: Therapeutic Replacement with Self-Amplifying RNA.Pharmaceutical research · 2026Review
- Immune Cell-Mediated Retinoblastoma Development: Genetic and Molecular Mechanisms.International journal of genomics · 2026Article
- A Perspective on Therapeutic Targeting Against Ubiquitin Ligases to Stabilize Tumor Suppressor Proteins.Cancers · 2025Review
- Identify Non-mutational p53 Functional Deficiency in Human Cancers.Genomics, proteomics & bioinformatics · 2024Article
- Article
- Decoding the molecular symphony: interactions between the mNAR cancer · 2024Review
- Therapeutic Strategies for RB1-Deficient Cancers: Intersecting Gene Regulation and Targeted Therapy.Cancers · 2024Review
- Ubiquitin-conjugating enzyme E2C (UBE2C) is a prognostic indicator for cholangiocarcinoma.European journal of medical research · 2023Article
- Detection of Biallelic Loss of DNA Repair Genes in Formalin-Fixed, Paraffin-Embedded Tumor Samples Using a Novel Tumor-Only Sequencing Panel.The Journal of molecular diagnostics : JMD · 2023Article
- Article
- Hereditary retinoblastoma iPSC model reveals aberrant spliceosome function driving bone malignancies.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Active mitochondrial respiration in cancer: a target for the drug.Molecular and cellular biochemistry · 2022Review
- An Integrative Transcriptomic and Methylation Approach for Identifying Differentially Expressed Circular RNAs Associated with DNA Methylation Change.Biomedicines · 2021Article
- Sex disparities matter in cancer development and therapy.Nature reviews. Cancer · 2021Review
- Article
- Mutation SVCT2 promotes cell proliferation, invasion and migration in colorectal cancer.Journal of Cancer · 2021Article
- Integrative Genomic and Transcriptomic Analyses of Tumor Suppressor Genes and Their Role on Tumor Microenvironment and Immunity in Lung Squamous Cell Carcinoma.Frontiers in immunology · 2021Article
- Observational
- Glutaminase 2 functions as a tumor suppressor gene in gastric cancer.Translational cancer research · 2020Article
- A reference profile-free deconvolution method to infer cancer cell-intrinsic subtypes and tumor-type-specific stromal profiles.Genome medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
We systematically investigated the landscape of tumor-suppressor gene (TSG) inactivation events in 33 cancer types by quantitatively measuring their global and local genomic features and their transcriptional and signaling footprints. Using The Cancer Genome Atlas data, we identified with high confidence 337 TSG × cancer events in 30 cancer types, of which 277 were unique events. The majority (91.0%) of these events had a significant downstream impact measured by reduced expression of the TSG itself (cis-effect), disturbance of the transcriptome (trans-effect), or combinatorial effects. Importantly, the transcriptomic changes associated with TSG inactivation events were stronger than the cancer lineage difference, and the same TSGs inactivated in different cancer types tended to cluster together. Several TSGs (e.g., RB1, TP53, and CDKN2A) involved in the regulation of the cell-cycle-formed clusters. Finally, we constructed subnetworks of the TSG × cancer inactivation events, including the local genes frequently disturbed upon the inactivation events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.